Cargando…
Splenic SUMO1 controls systemic inflammation in experimental sepsis
INTRODUCTION: The recent discovery of TAK981(Subasumstat), the first-in-class selective inhibitor of SUMOylation, enables new immune treatments. TAK981 is already in clinical trials to potentiate immunotherapy in metastatic tumors and hematologic malignancies. Cancer patients have more than ten time...
Autores principales: | Youssef, Ayman, Mohammed, Bilal Khan, Prasad, Abhishek, del Aguila, Angela, Bassi, Gabriel, Yang, Wei, Ulloa, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374847/ https://www.ncbi.nlm.nih.gov/pubmed/37520526 http://dx.doi.org/10.3389/fimmu.2023.1200939 |
Ejemplares similares
-
Dopaminergic Control of Inflammation and Glycemia in Sepsis and Diabetes
por: Feketeova, Eleonora, et al.
Publicado: (2018) -
Experimental Stroke Differentially Affects Discrete Subpopulations of Splenic Macrophages
por: McCulloch, Laura, et al.
Publicado: (2018) -
Splenic Nerve Neuromodulation Reduces Inflammation and Promotes Resolution in Chronically Implanted Pigs
por: Sokal, David M., et al.
Publicado: (2021) -
The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis
por: Gonçalves-de-Albuquerque, Cassiano Felippe, et al.
Publicado: (2018) -
Novel Insights for Systemic Inflammation in Sepsis and Hemorrhage
por: Cai, Bolin, et al.
Publicado: (2010)